This website uses cookies to improve user experience, to improve performance, and to analyze traffic to the website. By continuing to browse this website, you agree to the storage of cookies on your device. More information on cookies X

For US Healthcare Professionals
Connect With Us

Dosing & Administration

Dosing

VYJUVEK is a noninvasive topical gel with a weekly maximum dose dependent upon patient age1

Approximate treatment area of VYJUVEK™ for patients 6 months to 3 years of age. Approximate treatment area of VYJUVEK™ for patients 6 months to 3 years of age.
Approximate treatment area of VYJUVEK™ for 3 years of age and older. Approximate treatment area of VYJUVEK™ for 3 years of age and older.

*Images are illustrative. Total surface area covered may vary. Follow the 1 cm × 1 cm application process in section 2.3 of the full Prescribing Information.

Because there is a maximum weekly dose of VYJUVEK, wound treatment prioritization may be required.
Administration

VYJUVEK is administered weekly by a healthcare professional in‑home or in‑office1

VYJUVEK gel is applied in small droplets that are evenly spaced (1 cm × 1 cm apart) on the selected wounds to form a thin film after a hydrophobic dressing is applied. Proceed to treat other wounds until the maximum weekly dose is reached.1

  • Prior to application, VYJUVEK suspension must be mixed with excipient gel
  • VYJUVEK gel should be applied weekly to skin wounds until they are closed
  • The volume of VYJUVEK gel applied each week may vary, up to the maximum weekly dose, as wound size decreases or increases
  • Prioritize weekly treatment to previously treated wounds until closure before starting treatment of new wounds
  • Healthcare providers and close contacts should avoid direct contact with treated wounds and dressings for the first 24 hours following treatment
    • Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container
    • In the event of an accidental exposure, flush with clean water for at least 15 minutes
VYJUVEK™ vials VYJUVEK™ topical application to skin wounds
It is important to ensure weekly treatments with
VYJUVEK until wounds close.

Watch these videos to learn how to prepare and administer VYJUVEK

Preparing VYJUVEK
Administering VYJUVEK
Real-World Application of VYJUVEK Video – Isaiah Z
Download these brochures for
additional VYJUVEK instructions
Preparation Information Administration Guidance

Get your patients started on VYJUVEK with Krystal Connect™ patient support

Get Started
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


References

1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.

IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


References

1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.